HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a service system defined as "1+2+3+4=1" and can supply dibenzoylmethane from multiple well-known original manufacturers. As a technology-driven foreign trade enterprise, HiSiaddi has repeatedly proposed formula optimization solutions and application improvement suggestions for dibenzoylmethane through technological transformation cooperation with manufacturers and precise market demand insight. Below is a consultation case of HiSiaddi on formula optimization for dibenzoylmethane.
Contact HiSiaddi customer service if you require further formula optimization consultation services.
Purchaser: AUSTROMED PVC GmbH (Austromed Medical Plastics Co., Ltd., Austria), located in the industrial new zone near Vienna, Austria. With 31 years of experience manufacturing high-end transparent medical PVC consumables, its three core product lines include disposable sterile infusion catheters, transparent medical blister packaging and medical-grade flexible PVC films. All products are supplied to top tertiary hospitals in Austria, supporting supply chains of Bosch Medical (Germany) and Swiss pharmaceutical packaging groups. The full product line strictly complies with EU food-contact regulations EU10/2011, German LFGB and REACH control standards, and adopts eco-friendly lead-free calcium-zinc stabilization systems for all production. It is a benchmark medical plastics manufacturer in Central Europe.
For fifteen years, the enterprise has long purchased original high-purity dibenzoylmethane (DBM) from Eastman (USA) as a core auxiliary component of calcium-zinc composite stabilizers, with an annual stable procurement volume of 53 tons, relying on mature formulas with imported raw materials for stable mass production.
Against the backdrop of continuous price hikes of fine chemical raw materials in Europe and America, limited production capacity of overseas major manufacturers and sea transportation cycles extended to over 85 days in the past three years, the procurement department launched a domestic DBM substitution project. After preliminary sample screening, mid-to-high-end refined DBM from a leading domestic additive manufacturer was selected, with an initial 19 tons purchased for full replacement of imported raw materials across three medical PVC extrusion production lines.
After formal production launch with the original mature formula adapted to Eastman DBM and existing internal mixing and extrusion processes, four critical production failures emerged within just three days, forcing full temporary shutdown of the three medical production lines. All semi-finished products fed into production failed to meet medical light transmittance and safety standards, resulting in scrapped semi-finished products worth nearly 100,000 Euros.
The supplying manufacturer could only issue purity COA test certificates guaranteeing compliance with national standards, without internal PVC downstream formula application engineers. It lacked understanding of compatibility logic and processing adaptation details of DBM in transparent medical PVC systems, and failed to troubleshoot root causes from three dimensions: formula ratio, physical property differences of raw materials and workshop production parameters. Multiple online technical communications could not deliver rectification solutions. Recommended by the Austrian Plastics Industry Association, the enterprise fully entrusted HiSiaddi to set up a chemical technology expert group to complete fault tracing, formula revision and production process optimization through remote data sampling and formula review, providing one-stop full-process technical services.
1. Dense tiny precipitated white spots on PVC product surfaces with sharp drop in transparent substrate light transmittance Pinpoint irregular white spots and fine fog patches appeared on the tube walls of medical infusion catheters and transparent packaging films, reducing finished product light transmittance from 91.5% (with imported raw materials) to below 82%, failing visual acceptance standards for medical devices as judged by the client’s quality inspection department. Preliminary separate troubleshooting by the client confirmed white spots were incompletely melted and dispersed agglomerated DBM powder; solid raw material enrichment locally precipitated after high-temperature extrusion due to poor uniform fusion in plasticized systems during mixing.
2. Frequent zinc burning in mid-to-late processing, rapid yellowing of products under short-term heat exposure PVC billets after plasticization in the middle extruder section appeared white at first, but suffered rapid yellowing after molding at high die temperatures and 72-hour constant-temperature accelerated aging tests, with product yellowing index Δb＞3.2, far exceeding the enterprise’s internal medical raw material limit of ≤1.2. Raw materials stranded inside screws during shutdown partially blackened and carbonized, typical zinc burning failure of calcium-zinc systems. Domestic DBM failed to chelate zinc ions and capture hydrogen chloride generated by PVC decomposition as effectively as imported products, leading to insufficient synergistic stabilization performance.
3. Deteriorated storage stability of mixed materials after mixing, abnormal viscosity rise after standing at room temperature for 48 hours Fully pre-mixed PVC powder under the original formula agglomerated after sealed storage at room temperature for two days, increasing difficulty of high-speed mixing. Extrusion screw load fluctuated sharply with unstable discharging speed, frequent broken extrudate and die accumulation blockage halting production, significantly reducing production line operating rate.
4. Trace volatilization during high-temperature extrusion with slight migration precipitation after high-temperature boiling test of finished products Per EU medical consumable standards, a 95°C boiling test for 2 hours resulted in slight turbidity of soaking water, with trace small-molecule DBM impurities migrating and precipitating, failing LFGB food-contact raw material precipitation control limits and blocking access to EU medical packaging market approval.
HiSiaddi formed a special research team consisting of heat stabilizer application engineers, PVC formula R&D specialists and fine raw material physical & chemical analysts. It collected physical & chemical test data of domestic DBM and original Eastman DBM, full component lists of the client’s existing formula, extruder temperature parameters and internal mixer speed timing data, disassembling underlying root causes of the four failures item by item to clarify compatibility contradictions brought by subtle physical property differences between domestic and imported DBM, avoiding rectification misunderstandings of merely adjusting formulas while ignoring inherent raw material characteristics.
Original Eastman DBM undergoes multi-stage low-temperature air flow grinding at the factory with D50 particle size controlled below 3.2 μm, featuring loose porous powder that rapidly wets and dissolves in plasticizers such as DOP and epoxidized soybean oil at room temperature. In contrast, the refined domestic DBM purchased by the client meets national standard purity GC≥99.75% yet adopts conventional grinding processes resulting in D50=7.1~8.3 μm with coarse grains and high powder bulk density. The client retained the room-temperature direct feeding process designed for fine-grained imported materials: solid DBM was added all at once into mixtures of PVC resin and plasticizers. Coarse DBM particles failed to fully swell and disperse during low-speed mixing, forming agglomerated microcrystals at local over-saturation points that could not be completely melted in subsequent high-temperature extrusion, eventually precipitating as solid micro-particles to form white spots and fog patches. Meanwhile, natural short-wave ultraviolet light from daily lighting in the client’s batching workshop triggered slight premature decomposition of DBM, generating insoluble by-products that further increased white spot precipitation risks.
The original imported raw material formula contained DBM at a dosage of 0.85 phr (0.85 parts DBM per 100 parts PVC resin). Original Eastman products had higher effective chelating component content with strictly controlled trace yellow-causing impurities. Despite slightly higher effective β-diketone main component content in domestic DBM, the client failed to reduce addition dosage. Excess DBM decomposed under heat to form chromophoric groups, aggravated by trace colored by-products retained from raw material synthesis, jointly inducing yellowing of products after aging. In addition, the ratio of zinc stearate to calcium stearate in the client’s formula was 3.2:1 with excessive zinc soap proportion. Zinc soap decomposed under heat to generate zinc chloride, a strong Lewis acid that rapidly catalyzes PVC dehydrochlorination degradation. Excess DBM could not sufficiently chelate and passivate zinc chloride, leading to severe zinc burning and rapid yellowing/carbonization of products.
The epoxidized soybean oil (ESO) selected in the client’s formula had an acid value of 0.78 mgKOH/g, containing trace free carboxylic acids from the oil itself. Under room-temperature storage, weak acid components slowly damaged the β-diketone molecular structure of DBM. DBM hydrolysis generated polar small molecules that continuously induced slight pre-crosslinking reactions inside the PVC system, leading to gradual molecular chain association and agglomeration of mixtures, manifested as rising viscosity and powder caking after storage, directly impairing subsequent extrusion plasticization stability.
Compared with the fully sealed negative pressure solvent removal process of Eastman’s original factory, the recrystallization solvent removal process of domestic DBM left a total of 126 ppm low-boiling solvents including methanol and isopropanol inside products. During high-temperature processing, low-molecular solvents carried partial small-molecule DBM impurities to migrate to product surfaces. The original imported formula relied on low residue properties of imported DBM without adding phosphite anti-migration auxiliaries; after adopting domestic raw materials with high small-molecule impurity content, the absence of auxiliary binding agents caused rapid impurity precipitation during boiling tests, violating EU medical compliance red lines.
Combining medical PVC compliance indicators and existing hardware conditions of the client’s production lines, HiSiaddi delivered implementation details from four dimensions: improved raw material pre-treatment, refined fine-tuning of formula components, optimized mixing procedures and revised extrusion temperature control parameters. All optimization schemes balanced medical compliance standards and implementation requirements without large-scale equipment renovation by the client.
First, renovate batching environment: install light-proof closed enclosures in the batching workshop and replace all lighting with yellow explosion-proof lamps to completely isolate ultraviolet light and prevent DBM deterioration via photolysis before feeding. Second, implement pre-dissolved mother liquor process: abandon direct solid powder feeding. Prepare 25% concentration DBM pre-dissolved mother liquor by soaking DBM in 15% proportion of epoxidized soybean oil from the formula with low-speed stirring at 50°C for 45 minutes in a yellow light closed workshop, then feed the liquid into the main mixing tank to drastically improve dispersion efficiency. Third, coordinate upstream suppliers to customize ultrafine grinding specifications for subsequent DBM batches with exclusive grade locked at D50≤3.8 μm, narrowing particle size gaps from the raw material end to permanently avoid poor dispersion issues.
1. Optimize formula addition dosage: reduce DBM dosage from original 0.85 phr to 0.58 phr. Relying on higher effective content of domestic DBM, reduce risks of yellowing induced by excessive decomposition while maintaining thermal stabilization efficiency.
2. Adjust calcium-zinc stabilizer ratio: revise calcium stearate : zinc stearate ratio from original 3.2:1 to 4.1:1, increasing calcium soap proportion. Calcium soap rapidly captures hydrogen chloride generated by PVC decomposition and passivates catalytic activity of zinc chloride formed from zinc soap, inhibiting zinc burning from the reaction mechanism.
3. Compound functional auxiliaries: add 0.32 phr phenyl phosphite auxiliary stabilizer into the formula. Phosphite forms a synergistic stabilization system with DBM to improve initial whiteness, capture trace peroxides, delay yellowing under long-term heat exposure and enhance long-term weather resistance.
Replace epoxidized soybean oil with low acid value medical-grade ESO with acid value ≤0.25 mgKOH/g to reduce system acidity at source. Add 0.18 phr hydrotalcite powder into the formula; hydrotalcite provides acid-base buffering effects to adsorb free carboxylic acids in the formula and block contact between acidic media and DBM triggering hydrolysis. After optimization, powder viscosity fluctuation of pre-mixed sealed materials stored at room temperature for 15 days is controlled within 5% without agglomeration, fully matching the client’s raw material turnover and warehousing cycle.
Formula adjustment: add 0.25 phr macromolecular chelating polyol auxiliaries that form coordination wrapping structures with small-molecule DBM impurities to bind small molecules and prevent migration precipitation. Process adjustment: split four-stage temperature control parameters of the extruder: feeding section 158°C, plasticization section 166°C, homogenization section 172°C, die head 176°C. Reduce overall processing temperature from original 180°C to lower DBM thermal volatilization probability and mitigate high-temperature migration risks. Meanwhile, require upstream manufacturers to optimize negative pressure solvent removal procedures for subsequent DBM batches to control product solvent residue ≤40 ppm, matching LFGB medical raw material limit standards.
HiSiaddi prepared 5 groups of gradient samples per optimization scheme. The client’s laboratory simultaneously conducted light transmittance tests, 72-hour accelerated aging yellowing tests and 95°C boiling migration tests. Optimized samples maintained stable light transmittance above 91%, yellowing index Δb≤1.1 and clear soaking water without turbidity after boiling, with all four indicators matching finished product standards of original Eastman materials, initially verifying effectiveness of formula optimization.
Select a single medical catheter production line to fully implement HiSiaddi’s complete operating specifications including mother liquor pre-dissolution, yellow light closed mixing and segmented temperature control. Continuous 24-hour uninterrupted mass production of medical infusion catheters achieved no broken extrudate or die accumulation blockage across the whole line, with clean finished product surfaces free of white spots and fog patches. Full physical, chemical and compliance inspections passed the client’s internal quality control and EU LFGB sampling audit at one time.
After stable compliance of pilot data, the remaining 19 tons of stocked domestic DBM were batched for feeding production following optimized pre-treatment processes and revised formulas. All three suspended production lines resumed full-capacity operation, and medical PVC consumables produced that month were fully delivered to downstream pharmaceutical clients, recovering order losses caused by previous production shutdowns.
1. Significant optimization of raw material procurement costs The comprehensive total cost of purchasing domestic DBM plus incremental formula auxiliary materials after finalized optimization is 27.3% lower than original Eastman raw materials. An annual procurement order of 53 tons was formally signed with monthly batch production and delivery, drastically cutting capital occupation for raw material stockpiling and risks of ultra-long import lead times.
2. Full-series long-term technical custody of formulas The client entrusted HiSiaddi with annual technical custody covering raw material selection, formula iteration and process debugging for its three categories of PVC products: transparent medical catheters, medical soft films and pharmaceutical packaging. Pre-compatibility tests of samples are uniformly arranged by HiSiaddi before arrival of each DBM batch to avoid production failures from raw material warehousing.
3. Supporting technical services for new product R&D For the client’s subsequent R&D of infant food-grade PVC nipple raw materials, HiSiaddi was entrusted to fine-tune formula parameters based on existing DBM grades, supporting completion of EU food-contact compliance testing and mass production process implementation.
4. Iterative upgrading of upstream manufacturer products Relying on measured parameters and optimized indicators from this high-end Austrian medical client, domestic DBM manufacturers finalized exclusive ultrafine low-residue DBM grades for medical and food applications. Supported by fully verified product indicators and complete application technical solutions, two additional leading Nordic medical plastic end clients in Hungary and Finland were developed via HiSiaddi, expanding overseas mid-to-high-end market sales channels.
1. Domestic DBM products are split into two major categories: general industrial grade and mid-to-high-end refined grade. Most manufacturers focus R&D on synthetic purity indicators and lack supporting R&D for formula compatibility and processing technologies across downstream PVC application scenarios, only capable of issuing basic physical & chemical COA reports. They lack technical reserves on synergistic mechanisms in transparent medical PVC calcium-zinc systems and hidden indicator impacts of particle size & solvent residue. European and American mid-to-high-end medical plastic enterprises formulate formulas around physical properties of imported Eastman DBM; direct full replacement of raw materials while retaining original formulas easily triggers mass production failures due to subtle differences in powder particle size, impurity content and effective components. End manufacturers cannot independently complete systematic rectification when contacting raw material factories directly.
2. The core competitiveness of HiSiaddi lies in forming a full technical closed loop covering raw material physical property analysis, failure mechanism tracing, refined formula improvement, workshop process implementation and subsequent customized raw material grade development, breaking away from single product sales thinking and delivering technical solutions rooted in end formulas and actual production conditions, filling the application technology gap between domestic additive manufacturers and overseas mid-to-high-end end producers.
3. For mid-to-high-end PVC purchasers targeting EU medical and food contact applications, besides raw material quality, supporting full-process formula optimization and production technical services constitute the core competitive advantage distinguishing professional foreign trade service providers from ordinary spot intermediaries or single factory sales representatives, and the decisive factor for signing long-term annual framework cooperation agreements.
Contact HiSiaddi customer service if you require further formula optimization consultation services.
+86-13120989737 
info@hisiaddi.com 
English
